dual PPARgamma agonists/aldose reductease inhibitors (Theravalues)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Namedual PPARgamma agonists/aldose reductease inhibitors (Theravalues)
Drug Alias Nametherapeutic program (Theravalues)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator-activated receptor γ agonistsAldose reductase inhibitors
TargetsAldose reductasePeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTheravalues Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheravalues Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A